Method for preparing encapsulated antiseptic dorogov's stimulator (ads fraction 2)

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to producing drug preparations, namely represents a process of producing microcapsules of the antiseptic Dorogov's stimulator (ADS fraction 2). The process of microencapsulation represents a method of a non-solvent addition; a microcapsule coating is kappa-carageenan, while a core is the ADS fraction 2.

EFFECT: implementing the invention provides simplifying and accelerating the process of microencapsulation, reduces the microencapsulation loss (higher weight yield).

1 dwg, 2 ex

 

In the patent of Russian Federation №2173140, IPC AC 009/50, AK 009/127, publ. 10.09.2001 method for obtaining kremnijorganicheskih microcapsules using a rotary cavitation plants with high shear effort and powerful acoustic phenomena of sound and ultrasound range for dispersion.

The disadvantage of this method is the use of special equipment - rotary-cavity setup, which has the ultrasonic action that affects the formation of microcapsules and can cause adverse reactions due to the fact that ultrasound destructive effect on the polymers of protein nature, therefore the proposed method is applicable when working with polymers of synthetic origin

In patent No. 2359662, IPC AC 009/56, A61J 003/07, B01J 013/02, A23L 001/00, publ. 27.06.2009 method for obtaining microcapsules of sodium chloride with the use of spray cooling in the spray tower Niro under the following conditions: air temperature at the inlet 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm/min Microcapsules according to the invention have improved stability and provide adjustable and/or prolonged release of the active ingredient.

The disadvantages of the method are the duration of the process and application is of special equipment, a set of conditions (temperature of inlet air 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm).

The closest is the way to patent No. 2134967, IPC A01N 53/00, A01N 25/28, publ. 27.08.1999. Water is dispersed solution of a mixture of natural lipids and a PYRETHROID insecticide in the weight ratio of 2-4: 1 in an organic solvent, which leads to simplification of the method of microencapsulation.

The disadvantage of this method is the dispersion in the aquatic environment, which makes the proposed method applicable to the production of microcapsules of water-soluble drugs in water-soluble polymers.

The technical problem of the invention is the simplification and acceleration of the process of production of microcapsules, the reduction of losses upon receipt of the microcapsules (increase in mass).

The technical result - obtaining encapsulated antiseptic, stimulant A. C. Dorogov (DCA 2 fraction).

The solution of the technical problem is achieved by a method of producing encapsulated particles of fat-soluble polymeric shell SDA 2 faction, as the shell of the microcapsules use of Kappa-carrageenan, as well as kernel - SDA 2 faction when receiving the encapsulated particles by precipitation with nerastvorim with the use of sulphuric ether as precipitator.

A distinctive feature before aguinaga method is to obtain microcapsules by precipitation with nerastvorim using sulphuric ether as a precipitator, and the use of Kappa-carageenan as shell particles and the SDA 2 fraction as a kernel.

The result of the proposed method is to obtain microcapsules SDA 2 fraction in the shell Kappa-caragonne.

SDA 2 fraction is a fabric preparation of animal origin. In its composition contains compounds with active sulfhydryl group, derivatives of aliphatic amines, carboxylic acids, aliphatic and cyclic hydrocarbons, derivatives of amides and water. The SDA-2 in oral application has an activating effect on the Central nervous system and autonomic nervous system, stimulates motor activity of the gastrointestinal tract, the secretion of digestive glands, increases the activity of the digestive and tissue enzymes, improves the penetration of the ions Na+ and K+ across cell membranes, helps normalize digestion, absorption of nutrients and increase the natural resistance of the organism. When applied externally, the drug stimulates the activity of the reticuloendothelial system, normalizes the trophic and accelerates regeneration of damaged tissues, has a strong antiseptic and anti-inflammatory action.

In Fig.1 presents microcapsules SDA 2 fraction in Kappa-carrageenan (ratio 1:3) and increase in 505 times, b - increase in RS, in increase to 930 times, the increase in 1200 times, Dr. increase in 1770 times, e - increase in 2830 times.

EXAMPLE 1

Obtaining microcapsules SDA 2 fraction in Kappa-carrageenan

100 mg SDA 2 fraction was dissolved in 1 ml of dimethylsulfoxide and the mixture was dispersed in a solution of carrageenan in ethanol containing the specified 300 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid, as Tihonova may be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 Rev/sec. Then poured 2 ml of sulphuric ether and 1 ml of water. The resulting suspension is filtered and dried at room temperature.

Received 0,396 g of powder of microcapsules. The yield was 99%.

EXAMPLE 2 Obtaining microcapsules SDA 2 fraction in Kappa-carrageenan

100 mg SDA 2 fraction was dissolved in 1 ml of dimethylsulfoxide and the mixture was dispersed in a solution of carrageenan in ethanol containing the specified 100 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid, as Tihonova, can b the th etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 Rev/sec. Then poured 2 ml of sulphuric ether and 1 ml of water. The resulting suspension is filtered and dried at room temperature.

Received 0,188 g of powder of microcapsules. The yield was 94%.

Thus, the obtained microcapsules SDA 2 fraction with a high output.

The method of producing encapsulated particles of antiseptic, stimulant Dorogov (DCA) 2 fraction, characterized in that as the shell is carrageenan, which is precipitated from a solution in ethanol in the presence of ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid by adding sulfuric ether as a precipitator, the drying of the particles is carried out at room temperature.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmaceutics, particularly to a method for producing calcium chloride microcapsules possessing supramolecular properties by a non-solvent addition differing by dissolving calcium chloride in water and dispersing in a carageenan suspension used as a microcapsule coating, in ethanol in the presence of the preparation E472c; that is followed by adding isopropanol, filtering and drying at room temperature.

EFFECT: implementing the invention enables simplifying and fastening the process of the microcapsule preparation and increasing higher microcapsule yield by physical-chemical method of the non-solvent addition.

2 ex, 12 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry, and represents a method for producing drug microcapsules by a non-solvent addition differing by the fact that the drugs represent cephalosporins, while the coating is human serum albumin deposited from an aqueous solution by adding carbinol as the non-solvent and isopropanol at 25°C.

EFFECT: invention provides simplifying and fastening the microencapsulation process, reducing the microencapsulation loss (higher weight yield).

3 ex

FIELD: chemistry.

SUBSTANCE: in the process of obtaining microcapsules by a physical-chemical method of precipitation by means of a non-solvent, a heterocyclic compound is dissolved in DMSO, the obtained solution is transferred into a PVP water solution, the first precipitating agent - a mixture of acetic acid in acetone, containing octyl ether of acridonacetic acid (OeAAA) as SAS, is added, and after that, the second precipitating agent - a mixture of OeAAA in acetone is added, the obtained suspension is filtered, washed with acetone and dried.

EFFECT: realisation of the invention makes it possible to simplify the process of obtaining microcapsules and increase the output by weight.

3 ex

FIELD: medicine.

SUBSTANCE: drug preparations are used as cephalosporin preparations, while a coating is α- and β-forms of human leukocyte interferon, which is deposited from an aqueous solution by adding ethanol as a non-solvent and isopropanol at 25°C.

EFFECT: method provides simplifying and accelerating the process of microcapsules of water-soluble cephalosporin preparations, reducing the loss accompanying the process of microcapsules, higher weight yield.

4 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining medication microcapsules, possessing supramolecular properties, by method of precipitation with non-solvent, characterised by the fact that fenbendazole is used as medication and xanthan gum, precipitated from solution in butanol by addition of methanol and water as non-solvent at 25°C, is used as envelope.

EFFECT: simplification and acceleration of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules, increase of output by weight.

4 ex, 12 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for therapeutic preparation encapsulation by non-solvent addition, differing by the fact that the therapeutic preparation is presented by fenbendazole, while a coating is sodium carboxymethyl cellulose which is deposited from a solution of heptanes by adding isopropanole as a non-solvent and water at 25°C.

EFFECT: invention provides simplifying and accelerating the process of microcapsules, reducing loss accompanying microcapsule production (higher weight yield).

3 ex

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating antiseptic-stimulator Dorogova (ASD) fraction 2. The method is a physical-chemical non-solvent deposition method. When carrying out the method, the cladding of the microcapsules used is sodium alginate and the precipitation agent is carbon tetrachloride.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: distinctive feature of the present method is the use of betaine as an antioxidant and sodium alginate as a microcapsule envelope, as well as the use of tetrachloromethane as a precipitant when producing microcapsules using a physical-chemical non-solvent deposition method.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a method for a drug encapsulation by a non-solvent addition, differing by the fact that the drug is fenbendazole, and a coating is sodium carboxymethyl cellulose deposited from a heptane solution by adding methylcarbinol as the non-solvent and water at 25 °C.

EFFECT: invention provides simplifying and accelerating the process of preparing microcapsules, reducing the accompanying loss (higher weight yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to medicine, namely to oncology, and can be used in treating cancer in a patient. The method involves administering at least one encapsulated chemotherapeutic agent, and at least one amphiphilic block copolymer in this patient. What is also presented is a composition, a kit for treating cancer in the patient and using the amphiphilic block copolymer.

EFFECT: group of inventions provides potentiating the encapsulated chemotherapeutic agent by stimulating the active chemotherapeutic agent release from liposomes by the use of the amphiphilic block copolymer, which is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer, in the composition.

10 cl, 11 dwg, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely represents a method for ensuring a uniform dissolution profile of a pharmaceutical composition of cyclobenzaprine containing inert coated particles with the cyclobenzaprine containing composition of a drug layering for forming IR granules to be coated with a prolonged-release coating for forming ER granules.

EFFECT: developing the method for ensuring the uniform dissolution profile of the pharmaceutical composition.

53 cl, 6 ex, 5 dwg, 4 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to field of microcapsulation of heterocyclic compounds of triazine series, applied in pharmaceutical industry and agriculture as pesticides. Method of obtaining microcapsules includes physical-chemical method of precipitation with non-solvent with application of polyvinyl alcohol as microcapsule envelope. Carbinol and acetone are used as non-solvent. Preparation E 472c is used as emulsifier.

EFFECT: application of invention simplifies the process of obtaining microcapsules, increase of preparation output by weight.

3 ex

FIELD: chemistry.

SUBSTANCE: invention provides a method of encapsulating antiseptic-stimulator Dorogova (ASD) fraction 2. The method is a physical-chemical non-solvent deposition method. When carrying out the method, the cladding of the microcapsules used is sodium alginate and the precipitation agent is carbon tetrachloride.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: method of encapsulating creatine is a physical-chemical non-solvent deposition method. The envelope used is sodium alginate, which is deposited from a solution in butanol in the presence of a glycerol ester with one or two molecules of edible fatty acids and one or two molecules of citric acid by adding chloroform as a precipitant.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: distinctive feature of the present method is the use of betaine as an antioxidant and sodium alginate as a microcapsule envelope, as well as the use of tetrachloromethane as a precipitant when producing microcapsules using a physical-chemical non-solvent deposition method.

EFFECT: simple and faster process of producing microcapsules and higher mass output.

2 ex

FIELD: chemistry.

SUBSTANCE: described is method of obtaining particles of encapsulated with fat-soluble polymer envelope flavour enhancer, which possess supramolecular properties, with fat-soluble polymer being used as microcapsule envelope and flavour enhancer "gooseberry" being used as core in production of encapsulated particles by method of precipitation with non-solvent with application of acetone and butanol as precipitators.

EFFECT: simplification and acceleration of the process of producing microcapsules, reduction of loss in production of microcapsules.

1 dwg, 2 ex

FIELD: chemistry.

SUBSTANCE: method represents physico-chemical of precipitation with non-solvent, in which as microcapsule envelope xanthan gum, as core - ADS 2 fraction, and as precipitating agent - benzene are used.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increase of output by their weight.

3 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an oral pharmaceutical composition for treating intestinal disorders, containing butyric acid or its salt in a combination with water-soluble or water-dispersed dietary fibre specified in inulin, maltodextrin or a mixture thereof, at least one flavouring agent specified in vanillin, vanilla essence or a mixture thereof and one or more pharmacologically acceptable excipients differing by the fact that it contains: a) a matrix containing lipophilic compounds with a melting point of less than 90°C, and an amphiphilic matrix wherein an active ingredient is at least ball-shaped; b) an amphiphilic matrix; c) an outer hydrophilic matrix wherein the lipophilic matrix and the amphiphilic matrix are dispersed; e) a coating; and a portion of the above at least one flavouring agent is dispersed in one or more of the above matrixes, and a portion of the flavouring agent is dispersed in the coating.

EFFECT: preparing the pharmaceutical composition for treating intestinal disorders.

22 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions involving a pharmaceutical composition, a method of preparing it, a method of treating Parkinson's disease and a method of reducing a 'wear' effect in the given patients by administering the same. The pharmaceutical composition in the form of a single oral dose for treating Parkinson's disease consists of a mixture of a) Levodopa or its salt in an amount of 50 mg to 300 mg in the form of prolonged release, b) Carbidopa or its salt in an amount of 10 mg to 100 mg in the form of prolonged release, wherein the prolonged release is ensured by coating or mixing Levodopa and Carbidopa with one or more rate control polymers, and c) Entacapone or its salt in an amount of 100 mg to 1000 mg in the form of prolonged release, optionally with other pharmaceutically acceptable excipients.

EFFECT: group of inventions promotes patient's treatment compliance; using it leads to a stable blood content of active antigens and to reducing administration rate that provides reducing the 'wear' effect in the patients with Parkinson's disease; besides, the additional technical effect ensured by the composition consists in its stability at high temperature and humidity.

9 cl, 15 tbl

FIELD: chemistry.

SUBSTANCE: sodium carboxymethylcellulose is used as coating for microcapsules. Charge of fenbendazole, dissolved in dioxane, or dimethylsulphoxide, or dimethylformamide, is dispersed into solution of sodium carboxymethylcellulose in cyclohexanol in presence of surface-active substance E472c, mixing is performed at 1000 rev/s. Weight ratio of fenbendazole and sodium carboxymethylcellulose constitutes 1:3 respectively, after which mixture of butanol and distilled water taken in volume ratio 2:1 respectively is added, obtained suspension of microcapsules is filtered and dried. The process of obtaining fenbendazole microcapsules is realised at 25°C.

EFFECT: simplification and acceleration of the process of obtaining fenbendazole microcapsules in carboxymethylcellulose, reduction of loss in the process of obtaining microcapsules.

3 ex

Up!